Included in the formulation
АТХ:S.01.X.A Other drugs for the treatment of eye diseases
Pharmacodynamics:Pharmacological action - anti-cataract. Promotes the restoration of the permeability of the membrane and prevents the degeneration of the lens protein.
Competitively inhibits the action of quinone compounds (products of the disturbed metabolism of aromatic amino acids in the lens) and slows the process of coagulation (denaturation) - the transition of the soluble protein of the lens to an insoluble form - thereby delaying the development of cataracts. Normalizes the exchange of glucose in the lens and prevents the deposition of sorbitol. Stabilizes cell membranes, inhibits lipid peroxidation.
Pharmacokinetics:When instillation into the conjunctival sac 7 times with an interval of 5 minutes, the maximum concentration in the intraocular fluid - 0.0189 μg / ml, in the lens - 0.003 μg / ml, time to reach the maximum concentration in the intraocular fluid - 2 h, in the lens - 4 h. It binds to plasma proteins. It is excreted by the kidneys in an unchanged form (practically not metabolized).
Indications:Cataract: senile and diabetic.
VII.H25-H28.H28.0 * Diabetic cataract (E10-E14 + with common fourth sign .3)
VII.H25-H28.H26 Other cataracts
VII.H25-H28.H25 Star cataract
Contraindications:Hypersensitivity.
Carefully:Efficacy and safety of use in children have not been studied.
Pregnancy and lactation:Category of recommendations FDA is not defined. Adequate and well-controlled studies in humans and animals have not been conducted.
There is no information on the penetration into breast milk.
Dosing and Administration:Conjunctival. To prepare the solution, under sterile conditions, unscrew the cap of the vial-dropper with the solvent (15 ml) and lower into it a sterile tablet previously extracted from the package. After dissolution, a clear yellow solution is formed. The resulting solution is instilled in the conjunctival sac 1-2 drops 5-6 times daily for a long time.
Side effects:Itching, burning pain in the eyes, hyperemia sclera, superficial keratitis, marginal blepharitis, allergic reactions.
Occurrence of the expressed by-effects causes necessity of the termination of application.
Overdose:Not described. Treatment is symptomatic.
Interaction:Taurine increases the effect of pyreneoxin.
Special instructions:To avoid microbial contamination, it is not allowed to contact non-sterile objects with the tablet and the inner surface of the vial. The prepared solution can be stored for no more than 30 days in a cool place protected from light. When instilled, avoid contacting the tip of the pipette with the conjunctiva and skin of the eyelids.